The Pharmacology of Epanolol (ICI 141292–A New β1-Selective Adrenoceptor Partial Agonist

Bilski, Andrew J.; Hadfield, Sharon E.; Wale, Janet

doi:10.1097/00005344-198808000-00013

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epanolol (ICI 141,292, Visacor ®) is a ~l-selective adrenergic blocker with partial agonist activity (Bilski et al 1988). It might be used with other drugs, such as digoxin, in the treatment of cardiovascular diseases.…”

mentioning

confidence: 99%

Investigation of possible pharmacokinetic and pharmacodynamic interactions between epanolol and digoxin

Lefebvre

Bogaert

Duprez

1990

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The possibility of a pharmacokinetic and/or pharmacodynamic interaction between epanolol and digoxin has been investigated in 10 healthy male subjects taking digoxin 0.375 mg daily for 14 days. During that period epanolol 200 mg daily or matching placebo was also given, each for 7 days, according to a double-blind, randomized cross-over plan. The plasma digoxin concentration-time profiles after 7 days of concomitant placebo or epanolol were comparable. Trough and peak plasma digoxin levels were similar (placebo: 0.84 and 2.62 ng.ml-1; epanolol: 0.87 and 2.46 ng.ml-1). The renal clearances of digoxin and creatinine were lower during treatment with epanolol, but the differences were not significant (placebo 142.0 and 126.5 ml.min-1; epanolol 105.7 and 109.3 ml.min-1). STI indexes were lower during treatment with digoxin plus epanolol, than after digoxin alone. The difference was significant for QS2I (513 versus 503 ms), PEPI (119 versus 112 ms) and PEP/LVET (0.286 versus 0.304). The observations suggest that in healthy volunteers there is no pharmacokinetic interaction between epanolol and digoxin, and that epanolol does not interfere with the positive inotropic action of digoxin.

show abstract

mentioning

confidence: 99%

Investigation of possible pharmacokinetic and pharmacodynamic interactions between epanolol and digoxin

Lefebvre

Bogaert

Duprez

1990

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

β-Blockers

Conway¹,

Bilski²

1990

Pharmacology of Antihypertensive Therapeutics

View full text Add to dashboard Cite

Ultraschnell wirksame Betablocker Esmolol und Landiolol: Aktuelle Rolle in der Intensiv- und Notfallmedizin

Gassanov

Er²

2019

Dtsch med Wochenschr

View full text Add to dashboard Cite

ZusammenfassungDie schnell und kurzwirksamen Betablocker Esmolol und Landiolol sind zugelassen zur Therapie der supraventrikulären Tachykardien. Beide Substanzen sind kardioselektiv mit einer sehr hohen β1-Rezeptor-Selektivität.Esmolol und Landiolol können aufgrund ihrer pharmakologischen Eigenschaften eine Alternative zu anderen Substanzen in der Notfall- und Intensivmedizin sein. Die meisten klinischen Studien deuten auf einen günstigen Effekt der ultrakurz wirksamen Betablocker auf die Herzfrequenz und andere hämodynamische Parameter hin. Jedoch fehlen bisher die qualitativ hochwertigen Studien, die eine eindeutige Überlegenheit der beiden β-Adrenorezeptor-Antagonisten gegenüber den etablierten Wirkstoffen zeigen. Angesichts der aktuellen Datenlage bleibt der Einsatz der beiden Betablocker ausgewählten Patienten mit Tachyarrhythmien vorbehalten, die unzureichend auf die bisherige Therapie ansprechen.

show abstract

The Pharmacology of Epanolol (ICI 141292–A New β1-Selective Adrenoceptor Partial Agonist

Cited by 5 publications

References 0 publications

Investigation of possible pharmacokinetic and pharmacodynamic interactions between epanolol and digoxin

Investigation of possible pharmacokinetic and pharmacodynamic interactions between epanolol and digoxin

β-Blockers

Ultraschnell wirksame Betablocker Esmolol und Landiolol: Aktuelle Rolle in der Intensiv- und Notfallmedizin

Contact Info

Product

Resources

About